Hyderabad’s Genome Valley: Capitalising on the Life Sciences Growth Trajectory

India has emerged as a global life sciences hub, driven by the rapid expansion of pharmaceutical, biotechnology, and medical device companies in response to surging domestic and international demand.

Accelerated by the COVID-19 pandemic, the country’s bioeconomy sector, the third largest in the APAC region, is estimated to exceed USD 124 billion in 2024 and is projected to reach USD 150 billion by 2025 and USD 300 billion by 2030. The Indian pharmaceutical industry is also estimated to grow at a CAGR of over 10% to reach a size of USD 130 billion by 2030.

Telangana has emerged as a pivotal contributor to the country’s life sciences landscape, accounting for approximately one-third of the country's pharmaceutical production, one-fifth of pharmaceutical exports, and one-third of global vaccine production. The state's position as a pharmaceutical manufacturing hub has attracted significant investments, with over USD 1.49 billion channelled into the life sciences sector over the past four years.

Genome Valley in Hyderabad stands as India's first and largest life sciences manufacturing and R&D cluster undertaking research, training, and manufacturing. This planned ecosystem houses some of the world's top 10 R&D companies, leading vaccine manufacturers, and over 200 companies while a robust infrastructure for burgeoning start-ups.

With two life sciences incubators and an accelerator, the cluster boasts the country’s most concentrated hub for innovation in these sectors, replete with cutting-edge infrastructure.

Please click the download button to gain granular insights on the Genome Valley cluster, its development infrastructure, and how it can shape the future of India’s transforming life sciences sector.